#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: dapagliflozin
Dapagliflozin associated with reduced risk of total heart failure events and cardiovascular death
1. In this prespecified analysis of the DELIVER trial, among 6263 patients, dapagliflozin reduced the risk of total heart failure ...
Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER
1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin ...
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
#VisualAbstract: Dapaglifozin reduced risk of worsening heart failure or cardiovascular death among patients with heart failure
Click here to read this study in NEJM.
#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...
Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
The DAPA-HF trial: Dapagliflozin in patients with heart failure [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...